Navigation Links
Cell Biosciences Announces Publication in Nature Medicine
Date:4/13/2009

s system is an ultrasensitive nanofluidic immunoassay system designed to analyze extremely small biological samples. Traditional protein analysis techniques can require as many as 100,000 cells, which complicates protein analysis in limited samples. The Cell Biosciences system can measure cell signaling proteins reproducibly in as few as 25 cells.

About Cell Biosciences

Cell Biosciences is a private life sciences company focused on nanoproteomics. We develop instrumentation systems, software, and assay products that reveal previously undetectable information about cellular control pathways. Our customers include leading institutions in the fields of cancer research, stem cell biology, and diabetes. Our products enable researchers to uncover fundamental mechanisms controlling cell proliferation and cell death, to accelerate the development of new therapeutics, and to help identify new prognostic and diagnostic disease biomarkers. Cell Biosciences is located in Palo Alto, California. For more information, visit www.cellbiosciences.com.


'/>"/>
SOURCE Cell Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Biosciences Closes $10 Million Series C Financing
2. SAFC Biosciences(R) Expands Media Capability for Chinese Hamster Ovary (CHO) Cell Lines
3. SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free
4. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
5. Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development
6. WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research
7. Neurocrine Biosciences to Present at the Cowen and Company 29th Annual Health Care Conference
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. Pressure BioSciences, Inc. to Present at the EdgeWater Research Partners Spring 2009 Micro/Small-Cap Investor Conference
10. Speid & Associates Partners With Genizon BioSciences to Reduce Attrition Rates of New Drug Compounds
11. Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 2015  Alere Inc. (NYSE: ALR ) (the "Company") ... timely file its Quarterly Report on Form 10-Q for the ... has received a notice from the New York Stock Exchange ... the NYSE,s continued listing requirements under the timely filing criteria ... The reason for the delay relates to ...
(Date:5/26/2015)... 2015   PDI , a leader in ... Oakwood Healthcare in Dearborn, Mich. ... in Delivering the Difference , ... in building collaborative relationships between infection prevention (IP) ... Oakwood Healthcare,s infection preventionist, ...
(Date:5/26/2015)... ANGELES , 26. mája 2015 ... v mene svojej rodiny prezidentom Barackovi Obamovi a ... v súvislosti so stratou Dr. Rongxiang Xu ... http://photos.prnewswire.com/prnh/20150522/218111 Dr. Xu bol ... dobe a jeho odhodlanie v oblasti vedy a ...
(Date:5/26/2015)... Fluorinov Pharma (Fluorinov), a FACIT portfolio company, today announced ... its Board of Directors.  His appointment strengthens Fluorinov,s leadership ... accelerates its clinical development activities.  "On ... to welcome Luke to the Board of Directors.  Luke ... strength and success of multiple organizations," said Malik ...
Breaking Biology Technology:PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3Dr. Rongxiang Xu, O legende 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 3
... EPS increased 16.0 percent to $0.58 from $0.50 ... amortization of intangible assets from the 2003 spin-off, ... first-quarter 2008- Total net revenues increased 14.4 percent ... increased 21.0 percent to a record $2.3 billion- ...
... - Results to be Presented at World ... AB announced today that it has completed its open Phase ... nephropathy, a,glomerulonephritis leading to end-stage renal disease. Nefecon is an ... in the kidneys through suppression of the gut immune,system. , ...
... and safety agencies are unable to cope with the ... nanotechnology. The nation needs a new agency to address ... health and environmental impacts of the technically complex products ... landmark paper, Oversight of Next Generation Nanotechnology, J. Clarence ...
Cached Biology Technology:Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 2Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 3Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 4Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 5Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 6Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 7Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 8Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 9Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 10Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 11Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 12Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 13Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 14Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 15Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 16Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 17Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 18Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 19Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 20Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 21Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 22Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 23Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R) 2Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R) 3Former EPA official calls for new environmental and consumer protection agency 2
(Date:5/18/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/5/2015)... OXFORD, Conn. , May 5, 2015, NXT-ID, ... biometric authentication company focused on the growing mobile commerce market, ... the Company,s Chief Technology Officer, is presenting  at CARTES SECURE ... May 5-7, 2015. The three-day conference ... session David is speaking in is themed Global Fraud: ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... in how organisms grow and flourish, but studying their ... difficult. Now, a team of chemists and neurobiologists led ... Erin M. Schuman at the California Institute of Technology ... protein synthesis in specific locations. , The new method, ...
... at the University of Chicago show how the bacteria that ... how, by slightly altering one of the microbe's tools, the ... vaccine. , Both papers -- one published online July 28 ... Infection and Immunity -- focus on aspects of the type-III ...
... greatly benefit crop plants, scientists have deciphered the genome ... from diseases. , The research provides clues to better ... safeguards roots and seeds from infection by harmful microbes ... published in Nature Biotechnology and was scheduled to be ...
Cached Biology News:Protein synthesis can be controlled by light, opening way for new scientific, medical applications 2Protein synthesis can be controlled by light, opening way for new scientific, medical applications 3Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine 2Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine 3Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine 4Genome study of beneficial microbe may help boost plant health 2
... of several isoprostanes produced from arachidonic acid during ... in the rat. 8-iso PGE2 inhibits U-46619 or ... and 5 µM, respectively. When infused into the ... of 4 mg/kg/min, 8-iso PGE2 decreases the GFR ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... Centra-CL5R multi-purpose centrifuge offers both high-speed ... assortment of rotor options, making it ... applications., Maximum Versatility , High-speed ... angle rotors or high-volume (4 x 250mL) ...
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: